Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.
POSTED
06-23-21
Novartis and Hewlett Packard Enterprise Join Forces to Advance Novartis Global Health Efforts
POSTED
01-26-21
Novartis Releases 2020 Novartis in Society Report to Share Progress on Key Environmental, Social and Governance (ESG) Topics
At Novartis, we work to build trust with society and deliver long-term value to our stakeholders by embedding environmental, social and governance (ESG) topics into the core of our business strategy and operations. As a global company, we have a great responsibility and an even greater opportunit...
POSTED
04-22-20
Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
BASEL, April 20, 2020 /3BL Media/ - Novartis has reached an agreement with the US Food and Dr...
POSTED
04-15-20
Celebrating the First World Chagas Disease Day
For the first time in history, the global health community is preparing to celebrate World Chagas Disease Day. Novartis is joining the global movement to raise visibility and awareness of patients with Chagas disease1.
The COVID-19 pandemic is a public health em...
POSTED
04-06-20
Novartis and the Novartis US Foundation Establish USD 5 Million US COVID-19 Community Response Fund
Novartis announced today, that in response to the COVID-19 pandemic in the US, Novartis and the Novartis US Foundation have established a US COVID-19 Community Response Fund. The Fund will provide cash and in-kind donations totalling USD 5 million for immediate response and recovery efforts relat...
POSTED
03-26-20
Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic Alongside Bill & Melinda Gates Foundation
Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and experti...
POSTED
03-20-20
Novartis Commits to Donate up to 130 Million Doses of Hydroxychloroquine to Support the Global COVID-19 Pandemic Response
Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis i...
POSTED
03-04-20
International Research Partnership and EDCTP to Invest €44m in Next-generation Antimalarials to Combat Drug-resistant Malaria in Africa
The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium will support the development of new treatments for malaria in the most-at-risk populations, including...
POSTED
02-26-20
Novartis and DNDi to Collaborate on the Development of a New Oral Drug to Treat Visceral Leishmaniasis
Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, ...
POSTED
02-03-20
Just Released: 2019 Novartis in Society Report, Detailing Progress Made on Environmental, Social and Governance (ESG) Topics
February 3, 2020 - For the seventh consecutive year, Novartis is publishing an annual Novartis in Society ESG report. The report has been prepared in accordance with the GRI Standards: Core option. It supplements the “Build trust with society” section in the 2019 Novartis A...